Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy

Infants with KMT2A-rearranged B-cell acute lymphoblastic leukemia (ALL) have a dismal prognosis. Survival outcomes have remained static in recent decades despite treatment intensification and novel therapies are urgently required. KMT2A-rearranged infant ALL cells are characterized by an abundance o...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheung, Laurence C., Aya-Bonilla, Carlos, Cruickshank, Mark N., Chiu, Sung K., Kuek, Vincent, Anderson, Denise, Chua, Grace-Alyssa, Singh, Sajla, Oommen, Joyce, Ferrari, Emanuela, Hughes, Anastasia M., Ford, Jette, Kunold, Elena, Hesselman, Maria C., Post, Frederik, Faulk, Kelly E., Breese, Erin H., Guest, Erin M., Brown, Patrick A., Loh, Mignon L., Lock, Richard B., Kees, Ursula R., Jafari, Rozbeh, Malinge, Sébastien, Kotecha, Rishi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883157/
https://www.ncbi.nlm.nih.gov/pubmed/36380143
http://dx.doi.org/10.1038/s41375-022-01746-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9883157/
https://www.ncbi.nlm.nih.gov/pubmed/36380143
http://dx.doi.org/10.1038/s41375-022-01746-3

Ejemplares similares